BioCentury
ARTICLE | Preclinical News

Apelin is a potential sarcopenia therapeutic

July 30, 2018 9:41 PM UTC

A paper in Nature Medicine suggests that apelin (APLN) could help treat sarcopenia as well as serve as a biomarker of the age-related disease characterized by skeletal muscle loss.

Researchers from University of Toulouse and colleagues first observed that plasma APLN levels were reduced in a cohort of elderly patients with age-related loss of muscle in the Phase III MAPT trial. In a mouse model of aging, plasma APLN levels and skeletal muscle APLN and APLN receptor (APLNR; APJ) mRNA expression decreased with age...